Fibronostics and the associated logos are trademarks of Fibronostics.

Fibronostics is a global diagnostics innovator advancing non-invasive, AI-powered solutions for the early detection and monitoring of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). By transforming routine blood tests into actionable clinical insights, Fibronostics is reshaping liver care for both patients and providers.

At the core of its platform is LIVERFASt™, a proprietary diagnostic that combines 10 blood-based biomarkers with patient anthropometrics to assess liver fibrosis, inflammation, and steatosis. This test delivers a comprehensive SAF (Steatosis-Activity-Fibrosis) score, providing a non-invasive alternative to liver biopsy for staging MASLD and MASH .

Complementing this is LIVERSTAT™, a streamlined tool designed for primary care and population health settings. Utilizing seven standard biomarkers and patient data, LIVERSTAT™ offers rapid, cost-effective liver health assessments, facilitating early identification of at-risk individuals and enabling timely interventions .

Fibronostics' diagnostics are validated across diverse populations and seamlessly integrate into clinical workflows, supporting pharmaceutical development and public health initiatives. By prioritizing accessibility and precision, Fibronostics is empowering a proactive approach to liver disease management, aiming to reduce the global burden of MASLD and MASH.